J Cancer 2012; 3:152-157. doi:10.7150/jca.4378 This volume

Research Paper

Targeting the mTOR pathway in Chromophobe Kidney Cancer

Brian Shuch1, Srinivas Vourganti1, Julia C. Friend1, Lee M. Zehngebot2, W. Marston Linehan1, Ramaprasad Srinivasan1 ✉

1. Urologic Oncology Branch, National Cancer Institute, 10 Center Drive, CRC, Building 10, Room 1-5940, Bethesda, MD 20892, USA;
2. Orlando Oncology, Orlando, Florida, 2501 N. Orange Avenue, Ste. 381, Orlando, FL 32804, USA.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R. Targeting the mTOR pathway in Chromophobe Kidney Cancer. J Cancer 2012; 3:152-157. doi:10.7150/jca.4378. Available from https://www.jcancer.org/v03p0152.htm

File import instruction


Chromophobe kidney cancer accounts for approximately 5% of cases of renal cell carcinoma (RCC). While the genetics of clear cell RCC has been a major focus of research, little is known about the biology of chromophobe tumors. There is ample preclinical rationale for the use of targeted therapy in clear cell tumors, and agents targeting the VHL/HIF pathway are now widely used in clinical practice. However, there is limited experience with targeted agents in non-clear cell tumors. Recently, a few case reports have emerged which report the use of mTOR inhibitors in chromophobe tumors. Here, we report our experience with targeted therapy in a patient with advanced chromophobe RCC who had a durable partial response to temsirolimus. We also include a literature review summarizing the published experience with targeted therapeutic approaches in chromophobe RCC. Additionally, the preclinical rationale for the use of mTOR inhibitors in this population based on our characterization of the hereditary form of chromophobe kidney cancer, Birt-Hogg-Dube syndrome, is discussed.

Keywords: mTOR inhibitors, Chromophobe Kidney Cancer